Autologous T cell activation fosters venetoclax resistance in CLL: rationale for a combined therapy with the BCR kinase inhibitor GS-9973 and anti-CD20 mAbs.

ELIAS ESTEBAN ENRIQUE; ALMEJUN MARIA BELÉN; COLADO ANA; CORDINI, GREGORIO; VERGARA-RUBIO, MARICEF; PODAZA ENRIQUE; RISNIK DENISE; CABREJO, MARÍA; FERNANDEZ GRECCO HORACIO; BEZARES RAIMUNDO FERNANDO; CUSTIDIANO, MARÍA DEL ROSARIO; SANCHEZ AVALOS JULIO; GARATE GONZALO MARTÍN; BORGE MERCEDES; GIORDANO MIRTA; GAMBERALE, ROMINA

Workshop; 3rd IBAM-CLL; 2018

AutologousT cell activation fosters venetoclax resistance in CLL: rationale for acombined therapy with the BCR kinase inhibitor GS-9973 and anti-CD20 mAbs. Elías E; Almejún M; Colado A;Cordini G; Vergara-Rubio M; Podaza E; Risnik D; Cabrejo M; Fernandez-Grecco H;Bezares R; Custidiano M; Sanchez-Ávalos J; Vicente U; Garate G; Borge M;Giordano M; Gamberale R. 3er Congreso Iberoamericano deLeucemia Linfocítica Crónica 2018 (IBAM 2018), Buenos Aires, Argentina. Agosto2018. Número especial de la revista de la sociedad argentina de hematología(SAH), volumen 22, Agosto 2018